• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Ziarco founded with Series A financing

Ziarco founded with Series A financing

November 5, 2012
CenterWatch Staff

Recently founded Ziarco, a clinical-stage biotech focused on therapeutics targeting inflammatory and allergic diseases, has closed an initial $6 million tranche of Series A financing totaling $27 million. The round was led by Biotechnology Value Fund, with participation by Pfizer Venture Investments.

Concurrent with the financing, Ziarco has entered into an agreement with Pfizer for the exclusive worldwide rights to commercialize a portfolio of clinical, preclinical and research anti-inflammatory and anti-allergic assets. In return, Pfizer will receive equity, as well as certain product-based milestone and royalty payments. Ziarco will use the proceeds of the financing to continue development of these assets and advance proprietary research.

"Ziarco was founded to address the significant need that still exists for new, more effective ways to treat disorders underpinned by inflammatory and allergic pathobiology,” said Dr. Mike Yeadon, CEO of Ziarco. “Each program in development at Ziarco has the potential to be a first-in-class therapeutic and because they target critical points within inflammatory and allergic pathways they offer treatment options for diverse and difficult to manage diseases.”

In addition to Yeadon, formerly vice president and CSO of Pfizer's Allergy and Respiratory Research Unit, Ziarco was co-founded by three former Pfizer colleagues: Dr. Steve Liu, vice president and CSO; Dr. Lynn Purkins, vice president and head clinical development; and Dr. Arif Shivji, vice president and head of development operations and business development.

"Our most advanced clinical program is a histamine H4 receptor (H4R) antagonist, ZPL-3893787, which could potentially be used to treat several major diseases, including asthma, allergic rhinitis, pain and a variety of inflammatory skin conditions, said Liu. “This is supported by several other products in our pipeline, including a topical cPLA2 inhibitor which is the most advanced in development worldwide."

Ziarco also formalized its board of directors. In addition to Yeadon and Liu, the board will consist of Mark Lampert, Matthew Perry and Joseph Sum, all of whom are from BVF Partners.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing